European Commission allocates EUR 6 million to clinical trials for Alzheimer’s disease
Tuesday 24 May 2011
Within the context of the Seventh Framework Programme (FP7), the European Commission has awarded EUR 6 million to an international research consortium known as NILVAD. The aim of the consortium is to develop a new Alzheimer’s disease treatment.
NILVAD is comprised of 18 European universities, hospitals and pharmaceutical companies and includes Alzheimer Europe. It is led by Trinity College, Dublin, Ireland. It will conduct clinical trials of NILVADIPINE to determine whether it can improve memory and slow the rate of progression of Alzheimer’s disease. It is currently used to treat high blood pressure and has been shown to decrease the risk of developing dementia. The study will be conducted on around 500 people over an 18 month period.
For further information about participants and the project please Caoimhe Ní Lochlainn, Press Officer, Communications Office, Trinity College, Dublin 2, Ireland.